BETOPTIC PILO
LOE ApproachingNDAOPHTHALMICSUSPENSION/DROPS
Approved
Apr 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
BETOPTIC PILO by Alcon is clinical pharmacology betaxolol hydrochloride, a cardioselective (beta 1 ) adrenoceptor antagonist, does not have significant membrane-stabilizing (local anesthetic) activity and is devoid of intrinsic sympathomimetic action. Approved for elevated intraocular pressure in patients with primary open-angle glaucoma, ocular hypertension. First approved in 1997.
Drug data last refreshed 36m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BETOPTIC PILO is a fixed-dose ophthalmic suspension combining betaxolol (a cardioselective beta-1 antagonist) and pilocarpine (a direct-acting cholinergic agent) for topical ocular use. It treats elevated intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension by dual mechanism: betaxolol decreases aqueous humor production while pilocarpine increases aqueous humor outflow. The combination provides 1–3 mmHg additional IOP lowering versus betaxolol monotherapy.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); brand team likely focused on retention and lifecycle extension rather than growth.
Mechanism of Action
CLINICAL PHARMACOLOGY Betaxolol hydrochloride, a cardioselective (beta 1 ) adrenoceptor antagonist, does not have significant membrane-stabilizing (local anesthetic) activity and is devoid of intrinsic sympathomimetic action. Orally administered beta-adrenergic blocking agents reduce cardiac output…
Indications (2)
Worked on BETOPTIC PILO at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.